Related Experiment Video

Updated: Oct 14, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K

Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors:

Kyaw Z Thein1,2, Daniel D Karp3, Apostolia Tsimberidou3

  • 1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. theink@ohsu.edu.

Investigational New Drugs
|November 3, 2021
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K
Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel
08:29

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Published on: May 14, 2018

10.1K

Related Experiment Videos

Last Updated: Oct 14, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K
Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel
08:29

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Published on: May 14, 2018

10.1K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

Articles linked to this work by shared authors, journal, and citation graph.

The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.

Journal of immunotherapy and precision oncology·2026

Addition of immune checkpoint inhibitor to standard of care chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis.

Exploration of targeted anti-tumor therapy·2026

CT-based deep foundation model for predicting immune checkpoint inhibitor-induced pneumonitis risk in lung cancer.

Journal for immunotherapy of cancer·2026

Clinical determinants of survival outcomes and acute toxicity after adoptive cellular therapy for solid tumors.

Frontiers in immunology·2026

Evidence and gaps in tumor-agnostic therapies for breast cancer: a narrative review.

Translational breast cancer research : a journal focusing on translational research in breast cancer·2026

A phase II basket trial of DART SWOG S1609: the salivary gland tumor cohort.

Therapeutic advances in medical oncology·2026

Comparative efficacy of CLDN18.2-directed regimens in advanced gastric/gastroesophageal junction adenocarcinoma: a meta-analysis of single-arm trials.

Investigational new drugs·2026

Parthenolide enhances imatinib activity in gastrointestinal stromal tumor models through stress-associated apoptosis.

Investigational new drugs·2026

First-in-human phase I study of DT-9081, a selective EP4 receptor antagonist, in advanced solid tumors.

Investigational new drugs·2026

Qishen Yiqi Dripping Pills ameliorate doxorubicin-induced cardiotoxicity: a study based on bioinformatics and experimental verification.

Investigational new drugs·2026

Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic cancer treated with gemcitabine and nab-paclitaxel: an exploratory biomarker analysis of the GENESECT study.

Investigational new drugs·2026

Inhibition of SHP2 enhances the effects of selective receptor tyrosine kinase inhibitors in untreated preclinical models of RET-mutated thyroid cancer.

Investigational new drugs·2026

Necroptosis as a key player in cervical cancer progression and management: a systematic review and transcriptomic cross-study consensus analysis.

Apoptosis : an international journal on programmed cell death·2026

Pharmacogenomics of cancer therapy-related cardiomyopathy in childhood cancer survivors.

Pharmacogenomics·2026

Revisiting Cell Death in Colorectal Cancer: The Rise of Ferroptosis as a Therapeutic Opportunity.

Journal of cellular physiology·2026

Evaluating early systemic therapies in the neoadjuvant setting for the treatment of urological cancers.

Expert opinion on investigational drugs·2026

Advances in Oncologic Therapies During Pregnancy: Balancing Maternal Cure With Fetal Safety in Reproductive Cancers.

Technology in cancer research & treatment·2026

Closing the Loop on Stone Prevention: A Two-Cycle Audit of Recurrence Prevention Counselling After Ureteric Stone Management.

Cureus·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us